Burkina Faso vs Rwanda: Average non-HDL cholesterol levels
Burkina Faso
2.6
in 2018
Rwanda
2.6
in 2018
Burkina Faso rank
187th
Rwanda rank
187th
Average non-HDL cholesterol levels over time
- Burkina Faso
- Rwanda
How they compare
Burkina Faso currently reports 2.6 against 2.6 in Rwanda, a difference of 0.
The two have swapped places 12 times across 39 shared years of data; in 1980 it was Rwanda ahead.
Burkina Faso ranks 187th and Rwanda ranks 187th of 191 countries.
Burkina Faso has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Burkina Faso | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.13 | 2.11 | 0.02 | Burkina Faso |
| 1990s | 2.32 | 2.27 | 0.05 | Burkina Faso |
| 2000s | 2.46 | 2.43 | 0.03 | Burkina Faso |
| 2010s | 2.57 | 2.52 | 0.0444 | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Burkina Faso or Rwanda?
- Burkina Faso, at 2.6 against 2.6 in Rwanda as of 2018.
- What is the difference in average non-hdl cholesterol levels between Burkina Faso and Rwanda?
- 0, with Burkina Faso ahead.
- How many years of comparable data are there for Burkina Faso and Rwanda?
- 39 years are reported by both, from 1980 to 2018.
- How do Burkina Faso and Rwanda rank globally for average non-hdl cholesterol levels?
- Burkina Faso ranks 187th and Rwanda ranks 187th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.